{"id":"placebo-ibi112","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Rash"},{"rate":"5-10%","effect":"Pyrexia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by binding to the PD-1 receptor on T cells, preventing its interaction with PD-L1 ligands and thereby enhancing T cell activation and anti-tumor immune response.","oneSentence":"IBI112 is an anti-PD-1 monoclonal antibody.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:27:30.884Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"},{"name":"Head and neck squamous cell carcinoma"}]},"trialDetails":[{"nctId":"NCT07265284","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With Moderate to Severe Plaque Psoriasis","status":"RECRUITING","sponsor":"Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.","startDate":"2025-12-03","conditions":"Psoriasis","enrollment":104},{"nctId":"NCT05377580","phase":"PHASE2","title":"A Study to Evaluate IBI112 in the Treatment of Moderate to Severe Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2022-07-01","conditions":"Ulcerative Colitis (UC)","enrollment":150},{"nctId":"NCT06049810","phase":"PHASE3","title":"IBI112 in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2023-10-10","conditions":"Psoriasis","enrollment":566},{"nctId":"NCT05645627","phase":"PHASE3","title":"A Study to Evaluate IBI112 in the Treatment of Psoriasis With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2023-02-10","conditions":"Psoriasis","enrollment":500},{"nctId":"NCT05003531","phase":"PHASE2","title":"A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2021-09-23","conditions":"Psoriasis","enrollment":250},{"nctId":"NCT04511624","phase":"PHASE1","title":"Single Dose Tolerability and Pharmacokinetics of IBI112 in Healthy Subjects","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2020-08-27","conditions":"Healthy Subjects","enrollment":46}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"placebo /IBI112","genericName":"placebo /IBI112","companyName":"Innovent Biologics (Suzhou) Co. Ltd.","companyId":"innovent-biologics-suzhou-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"IBI112 is an anti-PD-1 monoclonal antibody. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}